(Insulin lispro + pramlintide) is under clinical development by Adocia and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Insulin lispro + pramlintide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Insulin lispro + pramlintide) overview
BioChaperone Lispro Pramlintide (insulin lispro in combination with pramlintide) is under development for the treatment of type 1 diabetes and obesity. It is administered through subcutaneous route. It acts by targeting amylin hormone and insulin receptor. The drug candidate is developed based on Biochaperone technology.
Adocia overview
Adocia is a clinical-stage biotech company that discovers and develops therapeutic solutions for chronic metabolic diseases including diabetes and obesity. The company’s clinical pipeline product includes Biochaperone Lispro – ultra-rapid insulin, Adoral Sema – GLP-1 Semaglutide, Biochaperone Combo – insulins combination, Adoshell Islets – immunoprotective scaffold for cell therapy, M1Pram – Type-1 Diabetes, Biochaperone Lispram – insulin-pramlintide combination, Adogel Sema – long-acting injectable and others. It also provides preclinical stage cell therapy concentrating on the development of a hydrogel scaffold for people diagnosed with type 1 diabetes. The company operates in France. Adocia is headquartered in Lyon, Auvergne-Rhone-Alpes, France.
For a complete picture of (Insulin lispro + pramlintide)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
